14-day Premium Trial Subscription Try For FreeTry Free
Date Action Amount Person Type
Nov 20, 2023 Buy 3 350 897 Luo Ying Stock Option (Right to Buy)
Nov 20, 2023 Buy 2 262 755 Luo Ying Stock Option (Right to Buy)
Nov 20, 2023 Buy 1 665 115 Ye Weiguo Stock Option (Right to Buy)
Nov 20, 2023 Buy 4 510 047 Ma Songjiang Stock Option (Right to Buy)
Nov 20, 2023 Buy 578 540 Chen Ruoyu Stock Option (Right to Buy)
Nov 20, 2023 Buy 170 417 Wu Charles C Stock Option (Right to Buy)
Oct 31, 2023 Buy 1 866 Luo Ying Stock Option (Right to Buy)
Oct 31, 2023 Buy 314 652 Eastling Thomas Wilson Stock Option (Right to Buy)
Oct 31, 2023 Buy 1 866 Eastling Thomas Wilson Stock Option (Right to Buy)
Oct 31, 2023 Buy 1 866 Parry Renate Stock Option (Right to Buy)
Oct 31, 2023 Buy 34 380 Chen Ruoyu Stock Option (Right to Buy)
Oct 31, 2023 Buy 341 652 Usman Nassim Stock Option (Right to Buy)
Oct 31, 2023 Buy 1 866 Usman Nassim Stock Option (Right to Buy)
Oct 31, 2023 Buy 1 866 Ying Han Stock Option (Right to Buy)
Oct 31, 2023 Buy 1 866 Carmichael Gordon Stock Option (Right to Buy)
Oct 30, 2023 Buy 2 840 376 Luo Ying Common Stock
Oct 30, 2023 Buy 63 588 119 Gni Group Ltd. Common Stock
Oct 30, 2023 Buy 0 Ma Songjiang Common Stock
Oct 30, 2023 Buy 0 Ma Songjiang
Oct 30, 2023 Buy 0 Parry Renate
Oct 30, 2023 Buy 0 Ying Han
Oct 30, 2023 Buy 0 Carmichael Gordon
Oct 30, 2023 Buy 0 Ye Weiguo
Oct 30, 2023 Buy 0 Chen Ruoyu
Oct 30, 2023 Buy 0 Wu Charles C
Oct 27, 2023 Buy 8 110 300 Gni Group Ltd. Series X Convertible Preferred Stock Warrant (Right to Buy)
Oct 27, 2023 Buy 811 Gni Group Ltd. Series X Convertible Preferred Stock
Oct 27, 2023 Buy 0 Gni Group Ltd. Common Stock
Oct 27, 2023 Buy 123 400 000 Gni Group Ltd. Series X Convertible Preferred Stock
Oct 27, 2023 Sell 5 371 304 Gni Hong Kong Ltd Common Stock
Oct 27, 2023 Sell 10 577 Gni Hong Kong Ltd Series X Convertible Preferred Stock
Aug 31, 2023 Sell 7 Miller Seline E. Series Y Preferred Stock
Aug 31, 2023 Sell 1 Usman Nassim Series Y Preferred Stock
Aug 31, 2023 Sell 28 Hunt Andrea Series Y Preferred Stock
Aug 31, 2023 Sell 5 371 Gni Group Ltd. Series Y Preferred Stock
Aug 31, 2023 Sell 24 Lawlor Augustine Series Y Preferred Stock
Dec 26, 2022 Buy 0 Eastling Thomas Wilson
Dec 26, 2022 Buy 0 Eastling Thomas Wilson
Dec 26, 2022 Buy 105 770 000 Gni Group Ltd. Series X Convertible Preferred Stock
Dec 26, 2022 Buy 0 Gni Group Ltd. Common Stock
Dec 26, 2022 Buy 0 Gni Group Ltd. Common Stock
Dec 26, 2022 Buy 0 Luo Ying
Dec 26, 2022 Buy 0 Luo Ying
Aug 09, 2022 Buy 3 250 Usman Nassim Common Stock
Aug 09, 2022 Buy 3 250 Miller Seline E. Common Stock
Aug 09, 2022 Buy 3 250 Blouse Grant E. Common Stock
Feb 11, 2022 Buy 107 500 Miller Seline E. Stock Option (Right to Buy)
Feb 11, 2022 Buy 200 000 Blouse Grant E. Stock Option (Right to Buy)
Feb 09, 2022 Buy 3 250 Usman Nassim Common Stock
Feb 09, 2022 Buy 3 250 Miller Seline E. Common Stock
Feb 09, 2022 Buy 3 250 Blouse Grant E. Common Stock
Jan 07, 2022 Buy 12 308 Williams Eddie Common Stock
Jan 07, 2022 Buy 12 855 Ling Geoffrey M.d. Common Stock
Jan 07, 2022 Buy 7 521 Hunt Andrea Common Stock
Oct 13, 2021 Buy 16 000 Miller Seline E. Stock Option (Right to Buy)
Oct 01, 2021 Buy 2 980 Williams Eddie Common Stock
Oct 01, 2021 Buy 2 858 Ling Geoffrey M.d. Common Stock
Oct 01, 2021 Buy 5 839 Lawlor Augustine Common Stock
Oct 01, 2021 Buy 1 824 Hunt Andrea Common Stock
Oct 01, 2021 Buy 3 588 Desouza Errol B Common Stock
Sep 09, 2021 Buy 28 000 Jew Jeanne Y Stock Option (Right to Buy)
Sep 09, 2021 Buy 0 Jew Jeanne Y
Aug 09, 2021 Buy 867 Usman Nassim Common Stock
Aug 09, 2021 Buy 639 Levy Howard Common Stock
Aug 09, 2021 Buy 1 163 Blouse Grant E. Common Stock
Jul 12, 2021 Buy 0 Blouse Grant E. Common Stock
Jul 12, 2021 Buy 30 000 Blouse Grant E. Stock Option (Right to Buy)
Jul 12, 2021 Buy 10 000 Blouse Grant E. Stock Option (Right to Buy)
Jul 12, 2021 Buy 18 000 Blouse Grant E. Stock Option (Right to Buy)
Jul 12, 2021 Buy 35 000 Blouse Grant E. Stock Option (Right to Buy)
Jul 12, 2021 Buy 38 500 Blouse Grant E. Stock Option (Right to Buy)
Jul 12, 2021 Buy 25 000 Blouse Grant E. Stock Option (Right to Buy)
Jul 01, 2021 Buy 1 414 Williams Eddie Common Stock
Jul 01, 2021 Buy 2 713 Ling Geoffrey M.d. Common Stock
Jul 01, 2021 Buy 5 542 Lawlor Augustine Common Stock
Jul 01, 2021 Buy 2 886 Hunt Andrea Common Stock
Jul 01, 2021 Buy 3 406 Desouza Errol B Common Stock
Jun 09, 2021 Buy 14 000 Williams Eddie Stock Option (Right to Buy)
Jun 09, 2021 Buy 14 000 Tetlow Sharon Stock Option (Right to Buy)
Jun 09, 2021 Buy 14 000 Ling Geoffrey M.d. Stock Option (Right to Buy)
Jun 09, 2021 Buy 14 000 Lawlor Augustine Stock Option (Right to Buy)
Jun 09, 2021 Buy 14 000 Hunt Andrea Stock Option (Right to Buy)
Jun 09, 2021 Buy 14 000 Desouza Errol B Stock Option (Right to Buy)
Apr 05, 2021 Sell 5 000 Usman Nassim Stock Option (Right to Buy)
Apr 05, 2021 Buy 5 000 Usman Nassim Common Stock
Apr 01, 2021 Buy 1 215 Williams Eddie Common Stock
Apr 01, 2021 Buy 2 331 Ling Geoffrey M.d. Common Stock
Apr 01, 2021 Buy 4 761 Lawlor Augustine Common Stock
Apr 01, 2021 Buy 2 480 Hunt Andrea Common Stock
Apr 01, 2021 Buy 2 926 Desouza Errol B Common Stock
Feb 09, 2021 Buy 582 Usman Nassim Common Stock
Feb 09, 2021 Buy 1 670 Levy Howard Common Stock
Feb 08, 2021 Buy 140 000 Usman Nassim Stock Option (Right to Buy)
Feb 08, 2021 Buy 54 000 Musil Clinton Stock Option (Right to Buy)
Feb 08, 2021 Buy 25 000 Levy Howard Stock Option (Right to Buy)
Feb 08, 2021 Buy 140 000 Usman Nassim Stock Option (Right to Buy)
Feb 08, 2021 Buy 54 000 Musil Clinton Stock Option (Right to Buy)
Feb 08, 2021 Buy 25 000 Levy Howard Stock Option (Right to Buy)
Jan 05, 2021 Buy 940 Williams Eddie Common Stock
Jan 05, 2021 Buy 1 782 Ling Geoffrey M.d. Common Stock
INSIDER POWER
75.696
Last 100 transactions
Buy: 318 090 847 | Sell: 5 392 312 (Shares)

Based on the 100 latest insides trades, we have calculated the insider power to be positive at a ratio of 75.696.

In total, the insiders bought 318 090 847 and sold 5 392 312 414 CBIO shares in the last 100 trades.

Click to get the best stock tips daily for free!

About Catalyst Biosciences

Catalyst Biosciences Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD);... CBIO Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT